Clinical Trial Update: Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of alpelisib in pediatric and adult patients with Megalencephaly-capillary Malformation Polymicrogyria Syndrome …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Megalencephaly-capillary Malformation Polymicrogyria Syndrome

Drugs mentioned

• Alpelisib (alpelisib)

Snippet

Sponsor: Centre Hospitalier Universitaire Dijon | Conditions: Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP) | Phase 2 | Status: RECRUITING